Hanmi Pharmaceutical said it has submitted an investigational new drug (IND) application for a phase 1 clinical trial of its obesity treatment candidate HM15275 to the Ministry of Food and Drug Safety (MFDS). Hanmi also plans to submit the IND application to the U.S. FDA this month. Hanmi ...